IL17A and rheumatoid arthritis: The consequences of Th17 plasticity in arthritis were initially unclear, as the switch from IL-17 to IFNγ seemed unlikely to drive significant pathology given that administration of recombinant IFNγ to patients with rheumatoid arthritis has no adverse consequences (18).